Therapy of scleroderma lung disease

Clinical Pulmonary Medicine

Volumn 3, Issue 6, 1996, Pages 314-322

  Bolster, Marcy B ^a,b   Silver, Richard M ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alveolitis; Bronchoalveolar lavage; Cyclophosphamide; Pulmonary hypertension; Scleroderma

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; PENICILLAMINE; PREDNISONE; PROSTACYCLIN DERIVATIVE;

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; EARLY DIAGNOSIS; HUMAN; LUNG ALVEOLITIS; LUNG LAVAGE; LUNG SCINTISCANNING; OPEN LUNG BIOPSY; PULMONARY HYPERTENSION; SCLERODERMA; TREATMENT PLANNING;

EID: 0030443162     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045413-199611000-00003     Document Type: Article

References (5)

1. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
2. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
3. Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med 1989;320:1333-40.
4. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
5. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144:706-13.